Cyanotech Reports Financial Results For Fiscal Year 2012

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the fourth quarter and fiscal year 2012, ended March 31, 2012.

Fiscal Year 2012

For fiscal year 2012 compared to fiscal year 2011, revenues were $24,631,000 compared to $16,827,000. Gross profit was $9,774,000, with gross profit margin of 39.7%, compared to gross profit of $6,341,000 and gross profit margin of 37.7%. Net income was $3,632,000 or $0.66 per diluted share, compared to net income of $1,730,000 or $0.32 per diluted share.

Highlighting the fiscal year 2012 results, Brent Bailey, President and CEO, noted:
  • Net sales increased $7.8 million or 46.4% over the prior year to a record $24.6 million, driven primarily by an increase in demand for astaxanthin products.
  • Gross margin increased to 39.7% from 37.7%, aided by the growth in higher margin astaxanthin sales.
  • Operating income increased $1.7 million or 136% to $2.9 million, driven by the net sales growth.
  • Net income increased $1.9 million or 110% to $3.6 million, driven by the volume increase and a partial reversal of the valuation allowance on our deferred tax asset.
  • Earnings per diluted share increased $0.34 to $0.66.
  • Cash from operating activities increased $3.3 million to $5.1 million, resulting from the increased volume and non-cash items such as stock option compensation and increases in accounts payable and accrued expenses.
  • Cash and cash equivalents at March 31, 2012 increased $3.0 million to $5.1 million. As a result, working capital increased $1.8 million or 29% to $8.1 million at March 31, 2012.

In addition, we continue to gain distribution on the mainland in the natural products channel where our Nutrex-Hawaii brand grew 72% in fiscal 2012.”

For the year, spirulina sales accounted for 35% of total revenues and natural astaxanthin sales for 65%. International sales were 33% of total sales.

Mr. Bailey commented, “We are pleased with our business results and made significant progress in improving our processes, systems, facilities and organization in fiscal 2012. We are focused on continuing to strengthen our infrastructure to support the substantial growth we expect to generate for the foreseeable future.”

Vice President and CFO Jolé Deal commented that “as part of strengthening our foundation, we’ve made significant improvements in the effectiveness of our internal controls and procedures. As a result, the material weakness that had been identified in previous years no longer exists.”

Fourth Quarter 2012

For the fourth quarter of fiscal 2012 compared to the fourth quarter of fiscal 2011, revenues were $5,986,000 compared to $5,218,000. Gross profit was $2,053,000, with gross profit margin of 34.3%, compared to gross profit of $1,798,000 and gross profit margin of 34.5%. Net income was $1,158,000 or $0.20 per diluted share, compared to net income of $795,000 or $0.14 per diluted share. Net income for the fourth quarter included a reversal of the valuation allowance on our deferred tax asset of $892,000 in the current year and $552,000 last year.

About CyanotechCyanotech Corporation, a world leader in microalgae technology, produces BioAstin® Natural Astaxanthin and Hawaiian Spirulina Pacifica®—all natural, functional nutrients that leverage our experience and reputation for quality, building nutritional brands which promote health and well being. Cyanotech's Spirulina products offer complete nutrition, and augment energy and immune response. They are FDA-reviewed and accepted as Generally Recognized as Safe (GRAS) for use in food products. BioAstin's superior antioxidant activity and ability to support and maintain a natural anti-inflammatory response enhance skin, muscle and joint health. All Cyanotech products are produced from microalgae grown at its 90-acre facility in Kona, Hawaii using patented and proprietary technology. Cyanotech distributes to nutritional supplement, nutraceutical and cosmeceutical manufacturers and marketers in more than 54 countries worldwide. Cyanotech was the first microalgae company in the world to obtain quality management standards ISO 9001:2000 certification and is GMP-certified by the Natural Products Association TM . Visit for more information.

“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, and availability of financing, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company’s recent Form 10-Q and annual Form 10-K filings with the Securities and Exchange Commission.

( Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company’s Form 10-K for the period ended March 31, 2012. As such the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company’s Form 10-Q and annual Form 10-K filings with the Securities and Exchange Commission.)



(Dollars in thousands except par value and number of shares)

March 31,
        2012       2011
(in thousands, except share data)
Current assets:
Cash and cash equivalents $ 5,061 $ 2,062
Accounts receivable, net of allowance for doubtful accounts of $16 in 2012 and $58 in 2011 2,373 2,641
Inventories, net 3,548 3,627
Deferred tax assets 137 17
Prepaid expenses and other current assets 300 134
Total current assets 11,419 8,481
Equipment and leasehold improvements, net 5,834 4,557
Deferred tax assets 1,307 535
Other assets 478 287
Total assets $ 19,038 $ 13,860
Current liabilities:
Current maturities of long-term debt $ 234 $ 204
Customer deposits 49 115
Accounts payable 1,726 1,054
Accrued expenses 1,352 823
Total current liabilities 3,361 2,196
Long-term debt, excluding current maturities 400 553
Deferred rent 12
Total liabilities 3,773 2,749
Commitments and contingencies
Stockholders’ equity:
Common stock of $0.02 par value, authorized 7,500,000 shares; issued and outstanding 5,440,968 shares at 2012 and 5,395,168 shares at 2011 109 108
Additional paid-in capital 28,324 27,803
Accumulated deficit (13,168 ) (16,800 )
Total stockholders’ equity 15,265 11,111
Total liabilities and stockholders’ equity $ 19,038 $ 13,860



(Dollars in thousands, except per share amounts)

Year ended March 31,
      2012     2011     2010
(in thousands, except per share data)
Net sales $ 24,631 $ 16,827 $ 15,742
Cost of sales 14,857 10,486 9,109
Gross profit 9,774 6,341 6,633
Operating expenses:
General and administrative 4,014 2,822 3,311
Sales and marketing 2,480 1,986 1,402
Research and development 320 282 264
Loss on disposal of equipment and leasehold improvements 57 22 155
Total operating expense 6,871 5,112 5,132
Income from operations 2,903 1,229 1,501
Other income (expense):
Interest expense, net (55 ) (70 ) (109 )
Other income, net 5 4 23
Total other expense, net (50 ) (66 ) (86 )
Income before income tax benefit (expense) 2,853 1,163 1,415
Income tax benefit (expense) 779 567 (24 )
Net income $ 3,632 $ 1,730 $ 1,391
Net income per share:
Basic $ 0.67 $ 0.32 $ 0.26
Diluted $ 0.66 $ 0.32 $ 0.26
Shares used in calculation of net income per share:
Basic 5,414 5,353 5,251
Diluted 5,534 5,413 5,346

Copyright Business Wire 2010

If you liked this article you might like

Healthcare Sector: High Quality Stocks At A Great Value

Healthcare Sector: High Quality Stocks At A Great Value

Cyanotech Stock Soars (CYAN)

Cyanotech Stock Soars (CYAN)

7 Stocks Hitting New 52-Week Highs

7 Stocks Hitting New 52-Week Highs